Research shows monoclonal antibody effective in multiple sclerosis
http://www.tradingmarkets.com/.site/news/Stock News/715117/
The antibody, which was genetically engineered for large-scale production, binds to myelin and the surface of cells in the brain and spinal cord, triggering the cells to begin the repair process called remyelination. The study was conducted using a laboratory mouse model of chronic progressive multiple sclerosis in humans. The antibody was delivered alone and in combination with the steroid methylprednisolone, remyelination was detected in both instances. The antibody is being developed by Mayo Clinic and Acorda Therapeutics.
Andrew Blight, chief scientific officer at Acorda, said: "We are excited to be collaborating with Mayo on the development of this therapy. The options for treatment of MS are still quite limited, and a new approach that could repair damage to the central nervous system would represent an important advance for the individuals who live with this disease."
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon
http://www.tradingmarkets.com/.site/news/Stock%20News/715117/Research shows monoclonal antibody effective in multiple sclerosis
Trading Markets (press release) - Los Angeles,CA,USA
Oct 18, 2007 (Datamonitor via COMTEX) -- ACOR | charts | news | PowerRating -- Researchers at Mayo Clinic have presented details from a preclinical study ...
See all stories on this topic
Genzyme's Campath Effective in MS
Forbes - NY,USA
AP 10.15.07, 11:00 AM ET Biotechnology company Genzyme Corp. said Monday its leukemia drug Campath was more effective than Merck KGaA's Rebif in treating ...
See all stories on this topic
Fluoxetine for Relapsing Multiple Sclerosis: Presented at ECTRIMS
DG News - USA
The study inclusion patients with confirmed relapsing-remitting (RR) or secondary progressive (SP) MS with exacerbations (one in the last year, ...
See all stories on this topic
Elan Says Has Tysabri Options
Houston Chronicle - United States
2007 AP NEW YORK — Elan Corporation Plc. said Monday it has several options for its share in the multiple sclerosis drug Tysabri if partner Biogen Idec Inc. ...
See all stories on this topic
THE medicine Man
Irish Independent - Dublin,Ireland
Corporate raider Carl Icahn's bid for pharmaceutical firm Biogen also puts Irish drug company Elan, which owns the other 50pc of wonder-drug Tysabri, ...
See all stories on this topic
Biogen bid has secured the survival of Elan
Irish Independent - Dublin,Ireland
Carl Icahn's bid for Biogen -- which jointly owns the MS drug Tysabri with Elan -- has put a floor under the Elan share price and allows investors to look ...
See all stories on this topic
Treosulfan.com - The official site for treosulfan information
Why is this medication prescribed?
Treosulfan is one of a group of anti-cancer medicines called 'alkylating agents', which works by preventing the growth and division of cells and therefore stops them increasing in numbers.
This medication is commonly used as a chemotherapy drug to treat ovarian cancer. Doctors also sometimes use it in high doses to treat people with leukaemia who are going to have a donor bone marrow or stem cell transplant.
Additionally, treosulfan is currently used in clinical trials on patients who desire to try a new treatment approach
http://www.treosulfan.com/
Romney's day of reckoning
Indianapolis Star - United States
He notes, "Romney's wife, Ann, has multiple sclerosis, a neurodegenerative disease that could be helped by stem cells. And Mitt comes out against it. ...
See all stories on this topic
Stem Cell Research Proceeds Apace, But Many Challenges Lie Ahead
BioResearch Online (press release) - Horsham,PA,USA
One effect of this is that when injected into a body, the cells automatically home in on inflamed tissue. In multiple sclerosis, for example, the cells find ...
See all stories on this topic
Insomnia drug falls short in clinical trial
MediciNova said its product MC-305 for the treatment of insomnia didn't achieve statistically significant results in a Phase 2 clinical trial involving 90 patients. The company said it would stop the insomnia trial but try to license the product for development in treating psychiatric disorders.
“As announced in June, we remain focused on advancing two core assets: MN-221 for the treatment of status asthmaticus, for which we recently announced positive Phase 2A data, and MN-166 for the treatment of multiple sclerosis, which also demonstrated positive clinical benefits in the first-year analysis of a two-year Phase 2 clinical trial,” CEO Yuichi Iwaki said.
Shares closed at $7.45 but dropped to $5.40 in after-hours trading.
MS 150 cyclists start first leg
San Antonio Express-News Sat, 20 Oct 2007 8:42 PM PDT
Injured Iraq veterans among riders raising funds for multiple sclerosis.
posted by Bill at 7:17 PM
0 Comments:
Post a Comment
<< Home